Clinical trial
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic…
NCT00303498 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00303498 |
|---|---|
| Title | A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure |
| Official title | A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diastolic Heart Failure |
| Intervention type | Drug |
| Interventions | Sitexsentin sodium, Placebo |
| Enrollment | 200 |
| Start date | Mar 27, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Mar 17, 2006 |
| Last update posted | Jan 4, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: